~~<i id='C43C39A0C2'><strike id='C43C39A0C2'><tt id='C43C39A0C2'><pre id='C43C39A0C2'></pre></tt></strike></i>~~

Home» comprehensive» entertainment

entertainment

author：Wikipedia 2025-09-28 16:42:52 Page View：863

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel
Next article： Medical records are filled with copy

knowledge

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

The boys, now 6, who are gene therapy’s ‘edge case’ problem

HiramSecrist(left),whohasDuchennemusculardystrophy,withhismother,KristenSecrist(center),andhisgrandm

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Cancer drug shortages' outsize impact on ovarian cancer patients

SarahEvans,ofSyracuse,N.Y.,hasbeenaffectedbyovariancancerdrugshortages.MichelleGabelforSTATSarahEvan

WSS

entertainment

entertainment

explore

knowledge

Cancer drug shortages' outsize impact on ovarian cancer patients